think in bold ways about new approaches to research disease mechanisms, drug development, and cell-based treatments for a range of diseases and gave rise to countless applications in regenerative
Production of recombinant therapeutic proteins using cell-based host expression system is regarded as the corner stone in the treatment of various life-threatening diseases including cancer and autoimmune diseases
decellularized matrices, synthetic and natural scaffolds as replacements to reconstruct the gut, or cell-based approaches such as tissue specific cells (smooth muscle cells, neural progenitor cells and epithelial cells
Throughout my career, I have been working on the development of a cell-based therapeutic for retinal degenerative diseases. Although unconventional and interdisciplinary, this project was long accommodated within
Stem cell-based therapy has emerged as a promising treatment option in regenerative medicine. However, targeted systemic delivery of therapeutic cells to the dysfunctional tissues remains one formidable challenge. Herein
understanding of the underlying mechanisms, there are currently no effective pharmacological or cell-based treatment of the disease with a mortality rate as high as 40%. Given that recent studies
application, it is mandatory to develop the other non-toxic nano-technological and/or cell-based delivery strategies to enhance the biocompatibility and accuracy of NCT for cancer treatment. Mesenchymal
screened extracts with biological activities to relieve oxaliplatin-mediated neurotoxicity using in vitro cell-based assays which employed the nerve growth factor (NGF)-induced neurite growth from rat pheochromocytoma…
screened extracts with biological activities to relieve oxaliplatin-mediated neurotoxicity using in vitro cell-based assays which employed the nerve growth factor (NGF)-induced neurite growth from rat pheochromocytoma…
Production of recombinant therapeutic proteins using cell-based host expression system is regarded as the corner stone in the treatment of various life-threatening diseases including cancer and autoimmune diseases
VEGF-A was demonstrated and the angiogenesis-inhibitory functions were confirmed, both in cell-based assays as well as a xenograft animal model. VEGFR1(D1-D3)-Fc was demonstrated
combining biophysical, structural biology and cell biology approaches. Finally, we showed in cell-based LC-MS lipidomics that the AA capturing property of Mp1p is functionally relevant because T. marneffei
Cell-based assays are essential to assess drug-mediated toxicity and cellular responses and to discover new chemical entities in the early phase of drug discovery. Cellular assays are usually
SIAT1 cells have the capacity to be considered as an alternative mean to manufacture cell-based flu vaccine, especially for the human strains (H1N1), due to its antigenic stability
provides a base for understanding pathomechanism of GNE myopathy and the opportunity of using cell-based assay for exploring pharmacological drug molecules
pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs) serve as promising source for cell-based therapies in regenerative medicine. However, optimal methods for transforming iPSCs into MSCs
ammonia detoxification and lowering of intracranial pressure indicating a neuroprotective effect of this cell-based therapy. Plans for clinical evaluation of the SRBAL are underway. In addition, we have bioengineered
spermatogonial stem cells (SSCs) may provide simple and non-controversial access to an individual cell-based therapy. These human studies are based on mouse models of germ stem cell reprogramming
diseases. Due to biosafety concerns and FDA regulations, autologous stem cells are preferable for cell-based therapies. Unfortunately, the quantity and quality of MSCs decrease with aging, inhibiting progress
shown to undergo myogenic differentiation. To evaluate whether DPC are suitable cell type in cell-based therapies for DMD, mouse dermal papillae were microdissected from hair follicles of the whisker
spermatogonial stem cells (SSCs) may provide simple and non-controversial access to an individual cell-based therapy. These human studies are based on mouse models of germ stem cell reprogramming
ammonia detoxification and lowering of intracranial pressure indicating a neuroprotective effect of this cell-based therapy. Plans for clinical evaluation of the SRBAL are underway. In addition, we have bioengineered
diseases. Due to biosafety concerns and FDA regulations, autologous stem cells are preferable for cell-based therapies. Unfortunately, the quantity and quality of MSCs decrease with aging, inhibiting progress
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.